Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services…
$20.20+0.70%
报价 2026-11-13
市值
$1.91B
EV
$2.83B
PE (TTM)
–
预期 PE (FY2026)
23.8x
52 周区间距高点 -21.9%
$8.87$25.88
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| FTREFortrea Holdings Inc. | $1.91B | +0.7% | -1.9% | 17.1% | – | 34.8x | 12.5x | |
| XNCRXencor, Inc. | $2.78B | -2.7% | +45.7% | 93.9% | – | – | – | |
| MRVIMaravai LifeSciences Holdings, Inc. | $2.14B | -1.8% | +16.0% | 34.6% | – | – | – | |
| VIRVir Biotechnology, Inc. | $1.71B | -17.8% | +1488.5% | 97.2% | – | – | – | |
| ANABAnaptysBio, Inc. | $1.38B | -3.2% | -32.8% | 99% | – | 27.8x | 76.5x | |
| KURAKura Oncology, Inc. | $713.9M | +4.6% | +5.9% | 94.7% | – | – | – | |
| AVBPArriVent BioPharma, Inc. Common Stock | $672.9M | -0.5% | -34.5% | 0% | – | – | – | |
| PHATPhathom Pharmaceuticals, Inc. | $492.6M | -2.7% | +80.5% | 80.7% | – | – | – | |
| PROKProKidney Corp. | $351.4M | -9.1% | 0.0% | -252.6% | – | – | – | |
| 同行中位数 | – | – | +10.9% | 87.3% | – | 27.8x | 76.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。